NobleBlocks

Research indexAnimal study

Decoding the interplay

Baena, Ricci, Coccia and 2 others

1 Jan 2025Open access

NobleIDark:/48914/w1/20260526/F21930F5DOI10.14232/syrptbrs.2025.73

Abstract

Lipid nanoparticles (LNPs) have proven to be effective mRNA delivery carriers, with significant potential in vaccine applications.Initially, it was believed that mRNA vaccines would primarily transfect muscle cells at the injection site, as still suggested by public health platforms like the CDC and Mayo Clinic.However, emerging evidence now points to antigenpresenting cells (APCs) as key players in mRNA translation and antigen presentation [1,2].In this study, we optimized an LNP formulation encapsulating green fluorescent protein (GFP) mRNA using multiple microfluidic devices, including Nanoassemblr, TAMARA, and Helix.Transitioning from one device to another was not straightforward.This underscored the necessity of device-specific parameter optimization to obtain reproducible formulations.The resulting LNPs exhibited ideal characteristics, with an average size of 80 nm, PDI lower than 0.2, a neutral surface charge and an RNA association efficiency around 90%. PBMCs from healthy donors were employed as a model to evaluate transfection within this cell population.Consistent with previous in vivo studies on APCs [1,2], we observed GFP expression in approximately 10% of the PBMC population, with monocytes being the primary cells responsible for GFP uptake and expression, as confirmed by flow cytometry.Importantly, no significant IL-6 production was observed, suggesting that the LNPs did not trigger a pro-inflammatory cytokine response.Viability assays confirmed minimal cytotoxicity.This study underscores the ability of LNPs to transfect PBMCs, resulting in protein expression from the delivered mRNA.Additionally, the data supports our LNP formulation as a safe and promising platform for future vaccine development.

Discussion

Citations

Topics

More

Suggest a correction or report